AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push
AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, in more than five years.
Last updated: 2026-06-24 14:45:32 ET
AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, in more than five years.
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a F...
While the market's enthusiasm for one of Zealand's experimental drugs has cooled, investors are shifting focus to amylin-based medicines as a growth d...
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE